These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 617780)

  • 21. Fibrinogen derivatives in plasma.
    Lane DA
    Br J Haematol; 1981 Mar; 47(3):329-35. PubMed ID: 6161635
    [No Abstract]   [Full Text] [Related]  

  • 22. Evidence for four different polymerization sites involved in human fibrin formation.
    Olexa SA; Budzynski AZ
    Proc Natl Acad Sci U S A; 1980 Mar; 77(3):1374-8. PubMed ID: 6929491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of blood coagulation by soluble fibrin complexes.
    Hansen MS; Bang NU; Barton RD; Mattler LE
    J Exp Med; 1975 May; 141(5):944-61. PubMed ID: 805207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative N-terminal analysis of fibrinogen-fibrin-related antigen [FR antigen] from human plasma.
    Harris JU; Johnson AJ; Merskey C; Wang MT; Robinson D
    Biochem J; 1979 Dec; 183(3):623-32. PubMed ID: 540036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated fibrin-related markers in patients with malignant diseases frequently associated with disseminated intravascular coagulation and venous thromboembolism.
    Yamashita Y; Wada H; Nomura H; Mizuno T; Saito K; Yamada N; Asanuma K; Usui M; Kamimoto Y; Matsumoto T; Ohishi K; Katayama N
    Intern Med; 2014; 53(5):413-9. PubMed ID: 24583428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticosteroids and experimental intravascular coagulation.
    Gerrits WB; Prakke EM; van der Meer J; Feltkamp-Vroom TM; Vreeken J
    Scand J Haematol; 1974; 13(1):5-10. PubMed ID: 4412660
    [No Abstract]   [Full Text] [Related]  

  • 27. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Determination of fibrinogen and fibrin degradation products (DFP) in the acute stage of myocardial infarction].
    Baele G; Mussche M; Vermeire P; Pannier R
    Arch Mal Coeur Vaiss; 1973 Apr; 66(4):427-9. PubMed ID: 4198846
    [No Abstract]   [Full Text] [Related]  

  • 29. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
    Lane DA; Preston FE; VanRoss ME; Kakkar VV
    Br J Haematol; 1978 Dec; 40(4):609-15. PubMed ID: 365218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disseminated intravascular coagulation following Echis carinatus venom in dogs: effects of a synthetic thrombin inhibitor.
    Schaeffer RC; Briston C; Chilton SM; Carlson RW
    J Lab Clin Med; 1986 Jun; 107(6):488-97. PubMed ID: 3086470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrin deposition and removal in disseminated intravascular coagulation induced by endotoxin and saline loading: radioautographic findings in rats.
    Heyes H; Mohr W; Theiss W
    Thromb Haemost; 1979 Feb; 40(3):499-511. PubMed ID: 425064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction.
    Francis CW; Connaghan DG; Scott WL; Marder VJ
    Circulation; 1987 Jun; 75(6):1170-7. PubMed ID: 3568326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
    Watanabe R; Wada H; Sakakura M; Mori Y; Nakasaki T; Okugawa Y; Gabazza EC; Hayashi T; Nishioka J; Suzuki K; Shiku H; Nobori T
    Am J Hematol; 2000 Sep; 65(1):35-40. PubMed ID: 10936861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombin-Fibrin(ogen) Interactions, Host Defense and Risk of Thrombosis.
    Hulshof AM; Hemker HC; Spronk HMH; Henskens YMC; Ten Cate H
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation.
    Wada H; Wakita Y; Nakase T; Shimura M; Hiyoyama K; Nagaya S; Deguchi H; Mori Y; Kaneko T; Deguchi K; Fujii J; Shiku H
    Am J Hematol; 1996 Apr; 51(4):255-60. PubMed ID: 8602623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
    Horan JT; Francis CW
    Semin Thromb Hemost; 2001 Dec; 27(6):657-66. PubMed ID: 11740689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fibrinogen-fibrin derivatives during difibrase therapy. Detection and course observations of high-molecular and low-molecular derivatives using agarose gel filtration].
    Asbeck F; Lechler E; van de Loo J
    Verh Dtsch Ges Inn Med; 1974; 80():1466-70. PubMed ID: 4454459
    [No Abstract]   [Full Text] [Related]  

  • 38. Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia: toward a better definition of DIC.
    Taylor FB; Wada H; Kinasewitz G
    Crit Care Med; 2000 Sep; 28(9 Suppl):S12-9. PubMed ID: 11007191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibronectin: blood turnover in normal animals and during intravascular coagulation.
    Sherman LA; Lee J
    Blood; 1982 Sep; 60(3):558-63. PubMed ID: 7104486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular marker for detecting hypercoagulable state].
    Magari Y; Mizunaga S; Ito M; Shibata T; Ito H
    Rinsho Byori; 1994 Jan; 42(1):22-33. PubMed ID: 8107279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.